The Salt Lake Tribune is reporting that public employees in the state of Utah could be paid by their insurance plan to fill prescriptions for high-cost drugs in Mexico instead of in their local pharmacies.
The Salt Lake Tribune is reporting that public employees in the state of Utah could be paid by their insurance plan to fill prescriptions for high-cost drugs in Mexico instead of in their local pharmacies.
PEHP Health and Benefits, a division of Utah Retirement Systems, is a nonprofit trust that provides health benefits to Utah’s public employees, including county, city, school, and other public workers.
According to PEHP’s members’ website, the Pharmacy Tourism Program allows members who are not enrolled in Medicare the option to fill select drugs in Tijuana, Mexico, rather than in their local pharmacies. For members with certain plan types, medications are covered by the payer’s pharmacy benefit at no extra cost, and members are allowed to fill a 90-day supply.
The payer also arranges and pays for roundtrip airfare from Utah to San Diego, California, as well as car transportation across the US—Mexico border to a facility in Tijuana that will dispense the drugs. Finally, patients who take the option to travel to Mexico are also paid a cash reward of $500.
Among the drugs that qualify for the tourism program plan are biologics etanercept (Enbrel), adalimumab (Humira), abatacept (Orencia), and ustekinumab (Stelara). Notably, potentially cost-saving biosimilars for etanercept and adalimumab have been approved by the FDA, but none of the biosimilar options have launched because of patent protection for the originator products.
Other drugs that qualify for the plan are products that treat multiple sclerosis (including glatiramer acetate, dimethyl fumarate, fingolimod, interferon, and teriflunomide) as well as therapies to treat psoriasis (apremilast), osteoporosis (teriparatide) and cancer (abiraterone).
According to the Tribune, state representative Norman Thurston, a Republican representing Provo, said of the plan, “Why wouldn’t we pay $300 to go to San Diego, drive across to Mexico and save the system tens of thousands of dollars? If it can be done safely, we should be all over that.”
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.